PARP Inhibitor Market Dynamics: A Podcast

PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.